CA2113614A1 - Methodes et compositions pour le traitement antimicrobien - Google Patents

Methodes et compositions pour le traitement antimicrobien

Info

Publication number
CA2113614A1
CA2113614A1 CA002113614A CA2113614A CA2113614A1 CA 2113614 A1 CA2113614 A1 CA 2113614A1 CA 002113614 A CA002113614 A CA 002113614A CA 2113614 A CA2113614 A CA 2113614A CA 2113614 A1 CA2113614 A1 CA 2113614A1
Authority
CA
Canada
Prior art keywords
bismuth subsalicylate
antimicrobial
treatment
safe
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002113614A
Other languages
English (en)
Inventor
Scott Donald Whalen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2113614A1 publication Critical patent/CA2113614A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002113614A 1991-07-24 1992-07-15 Methodes et compositions pour le traitement antimicrobien Abandoned CA2113614A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73540091A 1991-07-24 1991-07-24
US735,400 1991-07-24

Publications (1)

Publication Number Publication Date
CA2113614A1 true CA2113614A1 (fr) 1993-02-04

Family

ID=24955626

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002113614A Abandoned CA2113614A1 (fr) 1991-07-24 1992-07-15 Methodes et compositions pour le traitement antimicrobien

Country Status (10)

Country Link
EP (1) EP0595890A1 (fr)
JP (1) JPH06509340A (fr)
AU (1) AU2324392A (fr)
BR (1) BR9206300A (fr)
CA (1) CA2113614A1 (fr)
IE (1) IE922403A1 (fr)
MA (1) MA22597A1 (fr)
MX (1) MX9204338A (fr)
PT (1) PT100729A (fr)
WO (1) WO1993001818A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN771596A0 (en) * 1996-01-25 1996-02-15 Mclean, Allan Joseph Methods of and compositions for potentiating the action of agents active on cell-wall sites of susceptible bacteria
DE10236347A1 (de) † 2002-08-08 2004-02-19 Basf Coatings Ag Wäßrige Elektrotauchlacke, ihre Verwendung in Verfahren zur Beschichtung elektrisch leitfähiger Substrate sowie die Verwendung von Bismutverbindungen in diesen wäßrigen Elektrotauchlacken
WO2005014567A1 (fr) * 2003-08-12 2005-02-17 Biocon Limited Sel de bismuth a acide mycophenolique
MX2018011413A (es) * 2016-03-24 2019-01-10 Paratek Pharm Innc Metodos para tratar y prevenir infeccion por c. difficile.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0206625B1 (fr) * 1985-06-13 1992-09-30 Barry James Dr. Marshall Composés pour le traitement d'affections gastro-intestinales
US5196205A (en) * 1987-10-12 1993-03-23 Borody Thomas J Method for treatment of gastro intestinal disorders

Also Published As

Publication number Publication date
BR9206300A (pt) 1994-08-02
AU2324392A (en) 1993-02-23
EP0595890A1 (fr) 1994-05-11
JPH06509340A (ja) 1994-10-20
PT100729A (pt) 1993-10-29
WO1993001818A1 (fr) 1993-02-04
IE922403A1 (en) 1993-01-27
MA22597A1 (fr) 1993-04-01
MX9204338A (es) 1993-03-01

Similar Documents

Publication Publication Date Title
Marshall Treatment strategies for Helicobacter pylori infection
JP5469511B2 (ja) 微生物の院内感染症の治療用医薬の製造におけるタウロリジンまたはタウラルタムのような抗微生物薬剤の使用
JPH0794390B2 (ja) 胃腸疾患の治療のための医薬組成物
KR19990022220A (ko) 의료 용도의 미소-캡슐화된 락토바실러스
RU2116071C1 (ru) Лекарственные препараты, набор и способ лечения желудочно-кишечных заболеваний, вызываемых или опосредуемых заражением helicobaeter pylori
JP2009537547A (ja) 生物学的治療組成物およびその使用
CN106620649A (zh) 使用单剂量奥利万星的治疗方法
US8003118B2 (en) Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
Wapnick et al. Reduction of postoperative infection in elective colon surgery with preoperative administration of kanamycin and erythromycin
US20190307744A1 (en) Pharmaceutical compositions comprising clofazimine analog compound b746 or clofazimine analog compound b826
JP2002500189A5 (fr)
Ristuccia et al. Current concepts in antimicrobial therapy of prostatitis
Fabian et al. Antibiotics in penetrating abdominal trauma: comparison of ticarcillin plus clavulanic acid with gentamicin plus clindamycin
KR100550839B1 (ko) 항균제
AU8424091A (en) Pharmaceutical compositions containing 5-difluoromethoxy-2-{(3,4-dimethoxy-2-pyridyl) methylsulfinyl} benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders
US3949077A (en) Synergistic antibiotic compositions
Sartori et al. Acute gastroduodenal mucosal injury after cisplatin plus etoposide chemotherapy: clinical and endoscopic study
EP0595890A1 (fr) Procedes et compositions de traitement antimicrobien
EP0591446B1 (fr) Procede de traitement des gastrites a helicobacter pylori
Glupczynski In vitro susceptibility of Helicobacter pylori to antibiotics and bismuth salts and the importance of acquired resistance to antibiotics in treatment failures of H. pylori infection
Pimentel et al. Efficacy and safety of norfloxacin 800 mg once-daily versus norfloxacin 400 mg twice-daily in the treatment of uncomplicated urinary tract infections in women: a double-blind, randomized clinical trial
NAKAYA et al. Antimicrobial agents and intestinal microflora
Slack et al. The microbiological and pharmacokinetic profile of an antibacterial agent useful for the single-dose therapy of urinary tract infection
Sharma et al. Cefuroxime Axetil: An oral prodrug of cefuroxime sodium
JPH11504940A (ja) 胃腸障害の治療及び予防用のビスマス及び１以上の抗微生物剤含有組成物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead